[1]邓蕊 李洪仕 蔡衡.左心耳封堵术对非瓣膜性心房颤动合并冠状动脉性心脏病的价值[J].心血管病学进展,2022,(11):966.[doi:10.16806/j.cnki.issn.1004-3934.2022.11.002]
　DENG Rui,LI Hongshi,CAI Heng.Value of Left Atrial Appendage Closure on Non-Valvular Atrial Fibrillation with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2022,(11):966.[doi:10.16806/j.cnki.issn.1004-3934.2022.11.002]
点击复制

左心耳封堵术对非瓣膜性心房颤动合并冠状动脉性心脏病的价值()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年11期
页码:
966
栏目:
综述
出版日期:
2022-11-25

文章信息/Info

Title:
Value of Left Atrial Appendage Closure on Non-Valvular Atrial Fibrillation with Coronary Heart Disease
作者:
邓蕊 李洪仕 蔡衡
(天津医科大学总医院心血管内科,天津 300052)
Author(s):
DENG Rui; LI Hongshi; CAI Heng
(Department of CardiologyTianjin Medical University General Hospital,Tianjin 300052,China)
关键词:
非瓣膜性心房颤动; 冠状动脉性心脏病; 左心耳封堵术
Keywords:
Non-valvular atrial fibrillation; Coronary heart disease; Left atrial appendage closure
DOI:
10.16806/j.cnki.issn.1004-3934.2022.11.002
摘要:
非瓣膜性心房颤动合并冠状动脉性心脏病患者的抗栓策略目前尚存争议，部分患者面临高缺血和/或高出血风险。现有指南大多推荐心房颤动合并急性冠脉综合征和/或经皮冠状动脉介入治疗患者应于早期接受三联抗栓治疗，推荐心房颤动合并慢性冠脉综合征患者接受单联口服抗凝药物预防缺血性心脑血管事件，但缺血与出血事件的有效平衡仍是临床中的棘手问题。左心耳封堵术作为心房颤动患者的抗凝替代治疗可同时减少缺血和出血事件，或可改变心房颤动合并冠状动脉性心脏病患者的治疗格局，现就这一领域的相关进展进行综述。
Abstract:
The anti-thrombotic strategies in patients of non-valvular atrial fibrillation with coronary heart disease are currently controversial,and some patients are facing with high ischemic and/or high hemorrhagic risk. Most of the guidelines recommend that the atrial fibrillation with acute coronary syndrome and/or with percutaneous coronary artery intervention patients should receive triple anti-thrombotic therapy in the early stage,and atrial fibrillation with chronic coronary syndrome patients should accept single anticoagulant therapy to prevent ischemic cardiovascular and cerebrovascular incidents. But the effective balance of ischemic and hemorrhagic events are still a difficult problem in clinical practice. Left atrial appendage closure,as anti-coagulation replacement therapy in patients with atrial fibrillation,can simultaneously reduce ischemic and hemorrhagic incidents,which can change the treatment pattern of patients with atrial fibrillation with coronary heart disease. This article will review related progress in this field

参考文献/References:

[1] Knuuti J,Wijns W,Saraste A,et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J,2020,41(3):407-477.

[2] Andrade J,Deyell M,Wong G,et al. Antithrombotic therapy for atrial fibrillation and coronary disease demystified[J]. Can J Cardiol,2018,34(11):1426-1436.

[3] Watson T,Shantsila E,Lip GY. Mechanisms of thrombogenesis in atrial fibrillation:Virchow’s triad revisited[J]. Lancet,2009,373(9658):155-166.

[4] Calenda BW,Fuster V,Halperin JL,et al. Stroke risk assessment in atrial fibrillation:risk factors and markers of atrial myopathy[J]. Nat Rev Cardiol,2016,13(9):549-559.

[5] Bisbal F,Baranchuk A,Braunwald E,et al. Atrial failure as a clinical entity:JACC review topic of the week[J]. J Am Coll Cardiol ,2020,75(2):222-232.

[6] Libby P,Buring JE,Badimon L,et al. Atherosclerosis[J]. Nat Rev Dis Primers,2019,5(1):56.

[7] Bentzon JF,Otsuka F,Virmani R,et al. Mechanisms of plaque formation and rupture[J]. Circ Res,2014,114(12):1852-1866.

[8] Connolly S,Eikelboom JW,Bosch J,et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease:an international,randomised,double-blind,placebo-controlled trial[J]. Lancet,2018,391(10117):205-218.

[9] ACTIVE Writing Group of the ACTIVE Investigators,Connolly S,Pogue J,et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events(ACTIVE W):a randomised controlled trial[J]. Lancet,2006,367(9526):1903-1912.

[10] Rivera-Caravaca JM,Roldán V,Esteve-Pastor MA,et al. Long-term stroke risk prediction in patients with atrial fibrillation:comparison of the ABC-stroke and CHA2DS2-VASc scores[J]. J Am Heart Assoc,2017,6(7):e006490.

[11] Roldán V,Rivera-Caravaca JM,Shantsila A,et al. Enhancing the ’real world’ prediction of cardiovascular events and major bleeding with the CHA2DS2-VASc and HAS-BLED scores using multiple biomarkers[J]. Ann Med,2018,50(1):26-34.

[12] Fauchier L,Lecoq C,Ancedy Y,et al. Evaluation of 5 prognostic scores for prediction of stroke,thromboembolic and coronary events,all-cause mortality,and major adverse cardiac events in patients with atrial fibrillation and coronary stenting[J]. Am J Cardiol,2016,118(5):700-707.

[13]Lip GYH,Collet JP,Haude M,et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions:a joint consensus document of the European Heart Rhythm Association(EHRA),European Society of Cardiology Working Group on Thrombosis,European Association of Percutaneous Cardiovascular Interventions(EAPCI),and European Association of Acute Cardiac Care(ACCA) endorsed by the Heart Rhythm Society(HRS),Asia-Pacific Heart Rhythm Society(APHRS),Latin America Heart Rhythm Society(LAHRS),and Cardiac Arrhythmia Society of Southern Africa(CASSA)[J]. Europace,2019,21(2):192-193.

[14] Angiolillo DJ,Goodman SG,Bhatt DL,et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention:a North American perspective —2018 update[J]. Circulation,2018,138(5):527-536.

[15] Kumbhani DJ,Cannon CP,Beavers CJ,et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease:a report of the American College of Cardiology Solution Set Oversight Committee[J]. J Am Coll Cardiol,2021,77(5):629-658.

[16] Lopes RD,Hong H,Harskamp RE,et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention:a network meta-analysis of randomized controlled trials[J]. JAMA Cardiol,2019,4(8):747-755.

[17] Gargiulo G,Goette A,Tijssen J,et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention:a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials[J]. Eur Heart J,2019,40(46):3757-3767.

[18] Yasuda S,Kaikita K,Akao M,et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease[J]. N Engl J Med,2019,381(12):1103-1113.

[19] Lip GY,Hammerstingl C,Marin F,et al. Left atrial thrombus resolution in atrial fibrillation or flutter:results of a prospective study with rivaroxaban(X-TRA) and a retrospective observational registry providing baseline data(CLOT-AF)[J]. Am Heart J,2016,178:126-134.

[20] Cresti A,García-Fernández MA,Sievert H,et al. Prevalence of extra-appendage thrombosis in non-valvular atrial fibrillation and atrial flutter in patients undergoing cardioversion:a large transoesophageal echo study[J]. EuroIntervention,2019,15(3):e225-e230.

[21] Hindricks G,Potpara T,Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS):the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC) Developed with the special contribution of the European Heart Rhythm Association(EHRA) of the ESC[J]. Eur Heart J,2021,42(5):373-498.

[22] Patel MR,Mahaffey KW,Garg J,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med,2011,365(10):883-891.

[23] Granger CB,Alexander JH,Mcmurray JJ,et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2011,365(11):981-992.

[24] Wallentin L,Yusuf S,Ezekowitz MD,et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation:an analysis of the RE-LY trial[J]. Lancet,2010,376(9745):975-983.

[25] Wang ZZ,Du X,Wang W,et al. Long-term persistence of newly initiated warfarin therapy in Chinese patients with nonvalvular atrial fibrillation[J]. Circ Cardiovasc Qual Outcomes,2016,9(4):380-387.

[26] Boersma LV,Ince H,Kische S,et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation:1-year follow-up outcome data of the EWOLUTION trial[J]. Heart Rhythm,2017,14(9):1302-1308.

[27] Boersma LV,Ince H,Kische S,et al. Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology:final 2-year outcome data of the EWOLUTION trial focusing on history of stroke and hemorrhage[J]. Circ Arrhythm Electrophysiol,2019,12(4):e006841.

[28] Boersma LV,Schmidt B,Betts TR,et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device:peri-procedural outcomes from the EWOLUTION registry[J]. Eur Heart J,2016,37(31):2465-2474.

[29] Holmes DR Jr,Kar S,Price M J,et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy:the PREVAIL trial[J]. J Am Coll Cardiol,2014,64(1):1-12.

[30] Holmes DR,Reddy VY,Turi ZG,et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation:a randomised non-inferiority trial[J]. Lancet,2009,374(9689):534-542.

[31] Reddy VY,Doshi SK,Kar S,et al. 5-Year outcomes after left atrial appendage closure:from the PREVAIL and PROTECT AF trials[J]. J Am Coll Cardiol,2017,70(24):2964-2975.

[32] Osmancik P,Tousek P,Herman D,et al. Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study)[J]. Am Heart J,2017,183:108-114.

[33] Osmancik P,Herman D,Neuzil P,et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation[J]. J Am Coll Cardiol,2020,75(25):3122-3135.

[34] Osmancik P,Herman D,Neuzil P,et al. 4-Year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation[J]. J Am Coll Cardiol,2022,79(1):1-14.

[35] Reddy VY,M?bius-Winkler S,Miller MA,et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation:the ASAP study(ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)[J]. J Am Coll Cardiol,2013,61(25):2551-2556.

[36] S?ndergaard L,Wong YH,Reddy VY,et al. Propensity-matched comparison of oral?anticoagulation versus antiplatelet therapy after left atrial appendage closure with WATCHMAN[J]. JACC Cardiovasc Interv,2019,12(11):1055-1063.

[37] Urena M,Rodés-Cabau J,Freixa X,et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy[J]. J Am Coll Cardiol,2013,62(2):96-102.

[38] Kook H,Kim H,Shim J,et al. Comparison of clinical outcomes between multiple antithrombotic therapy versus left atrial appendage occlusion with dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation[J]. PLoS One,2021,16(1):e0244723.

[39] Della Rocca DG,Magnocavallo M,di Biase L,et al. Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion[J]. JACC Cardiovasc Interv,2021,14(21):2353-2364.

[40] Melgaard L,Gorst-Rasmussen A,Lane DA,et al. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke,thromboembolism,and death in patients with heart failure with and without atrial fibrillation[J]. JAMA,2015,314(10):1030-1038.

[41] 王宇彬,刘庆荣,吴永健. 老年冠心病合并心房颤动患者的左心耳封堵治疗[J]. 中国医刊 ,2020,55(1):11-14.

相似文献/References:

[1]彭金华,王平,胡婧,等.左心耳封堵术对非瓣膜性心房颤动患者心脏利尿钠肽分泌功能的影响[J].心血管病学进展,2019,(6):873.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.009]
　PENG Jinhua,WANG PingHU Jing,YANG Jingqi,et al.Effect of Left Atrial Appendage Closure on Cardiac Natriuretic Peptide Secretion in Patients with Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(11):873.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.009]
[2]金铁托 阮中宝.左心耳封堵术对患者系统内稳态的影响[J].心血管病学进展,2020,(12):1268.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.011]
　JIN Tietuo,RUAN Zhongbao.Effect of Left Atrial Appendage Closure on Systemic Homeostasis in Patients[J].Advances in Cardiovascular Diseases,2020,(11):1268.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.011]
[3]秦可隽?姜述斌.左心耳封堵术对非瓣膜性心房颤动患者左心功能影响的研究进展[J].心血管病学进展,2024,(5):425.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.010]
　QIN KejuanJIANG Shubin.Effects of Left Atrial Appendage Closure on Left Heart Function in Patients with Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2024,(11):425.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.010]
[4]许溪麟 李小明.艾多沙班在心血管疾病应用的研究进展[J].心血管病学进展,2024,(5):451.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.016]
　XU Xilin,LI Xiaoming.Application of Edoxaban in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(11):451.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.016]
[5]杜朝慧 贺文凤 梁士楚 刘志月 黄鹤.非瓣膜性心房颤动患者左心房结构和功能的超声心动图评价进展[J].心血管病学进展,2024,(11):973.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.004]
　DU ChaohuiHE WenfengLIANG ShichuLIU ZhiyueHUANG He.Echocardiographic Assessment of Left Atrial Structure and Function in Patients with Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2024,(11):973.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.004]

更新日期/Last Update: 2023-01-31